AC
IRD

Annandale Capital’s Opus Genetics IRD Stock Holding History

Annandale Capital’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46K Hold
10,000
– – 0.01% 120
2025
Q4 		$20K Hold
10,000
– – ﹤0.01% 126
2025
Q3 		$165K Buy
+10,000
New +$12.4K ﹤0.01% 124

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Annandale Capital's IRD Position: Q1 2026 in Review

Annandale Capital held its Opus Genetics (IRD) position steady in Q1 2026 at 10,000 shares worth $46K. The position accounts for 0.01% of the portfolio, ranked #120.

Annandale Capital first reported a position in IRD in Q3 2025 and has held it in 3 quarters since. The position peaked at $165K in Q3 2025. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • Annandale Capital held 10,000 shares of Opus Genetics worth $46K as of Q1 2026.
  • Annandale Capital left its Opus Genetics share count unchanged in Q1 2026.
  • Opus Genetics made up 0.01% of Annandale Capital's portfolio in Q1 2026, its #120 holding.
  • Annandale Capital first reported a position in Opus Genetics in Q3 2025 and has held it in 3 quarters since.
  • Annandale Capital's Opus Genetics position peaked at $165K in Q3 2025.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on Annandale Capital's 13F filing for Q1 2026, filed 15 May 2026.